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Bifidobacteria are commensal microoganisms found in the gastrointestinal tract.
Several strains have been attributed beneficial traits at local and systemic levels,
through pathogen exclusion or immune modulation, among other benefits. This has
promoted a growing industrial and scientific interest in bifidobacteria as probiotic
supplements. However, the molecular mechanisms mediating this cross-talk with the
human host remain unknown. High-throughput technologies, from functional genomics
to transcriptomics, proteomics, and interactomics coupled to the development of both
in vitro and in vivo models to study the dynamics of the intestinal microbiota and their
effects on host cells, have eased the identification of key molecules in these interactions.
Numerous secreted or surface-associated proteins or peptides have been identified
as potential mediators of bifidobacteria-host interactions and molecular cross-talk,
directly participating in sensing environmental factors, promoting intestinal colonization,
or mediating a dialogue with mucosa-associated immune cells. On the other hand,
bifidobacteria induce the production of proteins in the intestine, by epithelial or immune
cells, and other gut bacteria, which are key elements in orchestrating interactions among
bifidobacteria, gut microbiota, and host cells. This review aims to give a comprehensive
overview on proteinaceous molecules described and characterized to date, as mediators
of the dynamic interplay between bifidobacteria and the human host, providing a
framework to identify knowledge gaps and future research needs.
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INTRODUCTION
The human gut is inhabited by a trillion of microorganisms which constitute the gut microbiota.
These microorganisms are in close contact with the intestinal mucosa, which represents the largest
extension of the human body exposed to external stimuli. A complex molecular interplay is
established among microbiota, dietary components and host cells, which regulates immune and
metabolic functions in the host (Furusawa et al., 2015). Dysbiosis, defined as changes in the gut
microbiota structure associated to healthy individuals, disrupts the microbiome-host cross-talk
homeostasis and correlates with metabolic and inflammatory disorders (Evans et al., 2013; Patel
et al., 2013; Levy et al., 2015).
Pro- and pre-biotics can improve host health through microbiota modulation and immune
system boosting (Picard et al., 2005). Some strains of bifidobacteria, which are among the first
colonizers of the human intestine and one of the dominant groups in the breast-fed infant
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microbiota (Garrido et al., 2012), have been attributed several
health benefits, encouraging interest in their use as probiotics.
Pathogen inhibition and diarrhea amelioration are their best
established outcomes and have been related to the production
of organic acids (Fukuda et al., 2011), antibacterial peptides
(Moroni et al., 2006), quorum-sensing inhibitors (Cotar et al.,
2010), pathogen displacement (Ruas-Madiedo et al., 2006), and
virulence attenuation (Tanner et al., 2016). Bifidobacteria also
regulate host functions and ferment complex polysaccharides
from our diet (Ménard et al., 2005; Heuvelin et al., 2009, 2010;
Bermudez-Brito et al., 2013; Furusawa et al., 2015), although
there is still limited knowledge on the molecular mechanisms
triggering these effects.
Delineating the specific molecules mediating Bifidobacterium
cross-talk with the host, will help to understand their beneficial
effects and establish microbiome-targeted therapies for human
diseases. This review gives an overview on molecules behind the
bifidobacterial-host cross-talk, providing a framework to design
safe and efficacious probiotic-derived supplements (Licciardi
et al., 2010; Shenderov, 2013).
INTESTINAL MUCOSA ADHESION
Bacterial adhesion to the intestinal surface is mediated by
non-specific, hydrophobic or electrostatic interactions, and
specific mechanisms involving macromolecular interactions
between bacterial and host receptors. Functionally characterized
Bifidobacterium adhesins, surface-associated proteins that
facilitate bifidobacteria attachment to intestinal cells and/or the
extracellular matrixes surrounding them, are reviewed below
and summarized in Figure 1.
Involvement of pili in bifidobacterial adhesion has been
studied in Bifidobacterium bifidum and Bifidobacterium breve
(O’Connell Motherway et al., 2011b; Turroni et al., 2013).
The B. bifidum PRL2010 genome harbors three pilus clusters.
Of these, pil2 and pil3, encode putative sortase-dependent pili
that are expressed under both in vitro and in vivo conditions.
Heterologous expression of pil3 in Lactococcus lactis significantly
increased this bacterium adhesion to the human epithelial
cell line Caco-2 (Turroni et al., 2013). The type IVb tight
adherence (Tad) pilus-encoding gene cluster from B. breve
UCC2003, was found to be essential for the colonization of,
and persistence in, the murine gut. Tad inactivation impaired
the strain ability to stably colonize the murine intestine, as
reflected by reduced shedding level and bifidobacterial numbers
in the gut (O’Connell Motherway et al., 2011b). Another surface-
anchored protein potentially involved in intestinal adhesion of
bifidobacteria is BopA. This purified lipoprotein competes with
B. bifidum MIMBb75 adhesion to Caco-2 cells, and probably
facilitates B. bifidum adhesion (Guglielmetti et al., 2008).
Indeed, Bifidobacterium strains overexpressing bopA adhere
better (Gleinser et al., 2012). However, B. bifidum treatment
with anti-BopA antibodies does not reduce the attachment
to intestinal cells (Kainulainen et al., 2013), thus the specific
adhesion mechanism mediated through BopA must be further
elucidated.
Remarkably, bifidobacteria can use some moonlighting
proteins, those with multiple functions (Jeffery, 2003), as
adhesin-like factors. Surface-exposed glycolytic enzymes,
including transaldolase from B. bifidum and enolase from
Bifidobacterium animalis, are adhere to mucin and plasminogen,
respectively (Candela et al., 2009; González-Rodríguez et al.,
2012). Other surface-exposed moonlighting proteins, including
the chaperone DnaK from B. animalis and the elongation
factor Tu from Bifidobacterium longum, showed high affinity
for human plasminogen in vitro and have been proposed as
mediators of intestinal attachment (Candela et al., 2010; Wei
et al., 2014).
It is worth highlighting that most of the adhesins herein
described have been identified on in vitro assays and their
relevance for intestinal colonization has not been tested in vivo.
Since laboratory models do not accurately mimic all the factors
that can affect bacterial attachment to the intestinal mucosa (e.g.,
due to the absence of a mucus layer and resident microbiota),
functional confirmation of the adhesion capacity in vivo is still
required (Ouwehand and Salminen, 2003).
TIGHT-JUNCTIONS
A single layer of epithelial cells provides a selective barrier
separating intestinal lumen from subjacent tissues. Tight-
junctions (TJ) are multi-protein complexes that control molecule
translocation across this barrier (Lee, 2015), and their disruption
leads to uncontrolled trafficking of noxious molecules triggering
inflammation (Bergmann et al., 2013).
Specific Bifidobacterium strains promote TJ enhancing
epithelial barrier integrity (Ohland and Macnaughton, 2010;
Mokkala et al., 2016). In animal models, B. bifidum and
B. longum strains preserved TJ localization, attenuating intestinal
permeability, and decreasing necrotizing enterocolitis incidence
(Khailova et al., 2009; Bergmann et al., 2013; Srutkova et al.,
2015). Preliminary work suggested that B. bifidum metabolites,
like acetate, induced TJ expression in intestinal cells (Hsieh et al.,
2015). Soluble factors present in B. longum lysates or secreted
by B. infantis or B. breve strains, also mediate epithelial barrier
maintenance (Ménard et al., 2005; Ewaschuk et al., 2008; Sultana
et al., 2013). Further research to identify the specific molecules
mediating this TJ promotion is needed.
MUCUS, HMO, AND NON-DIGESTIBLE
CARBOHYDRATES DEGRADATION
The spatial distribution of bacteria throughout the
gastrointestinal tract, is partly controlled by nutrients availability
for resident microbiota (Donaldson et al., 2016). Indeed, our
wellbeing relates with the nutrient harvesting capability of our
gut microbes. These microorganisms, overall, can utilize dietary
and host carbohydrates, and glycans produced by other gut
bacteria. Indeed, 89 “carbohydrate active enzymes” (CAZyme)
have recently been identified in 85% of the microbiomes obtained
from 488 individuals (Bhattacharya et al., 2015), suggesting that
gut bacteria are highly specialized in using available glycans as
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their main sustenance. Bifidobacterial genomes are abundant in
saccharolytic features whose expression is tightly regulated by
available carbohydrates (Khoroshkin et al., 2016), supporting
that host glycans were a potent evolutionary force driving their
successful gut colonization (Sánchez et al., 2013; Milani et al.,
2016).
Numerous studies demonstrated bifidobacteria’s capability
to use dietary non-digestible oligosaccharides, which is on
the basis of the prebiotic concept (Rastall and Gibson, 2015).
Glycosyl hydrolases (GH, or glycosidades), many of which
are extracellular, have high specificity for the oligosaccharides
constituents and cleave the glycosidic bonds (Table 1). Special
attention has been paid to the GH acting on human milk
oligosaccharides (HMO) since these serve as substrates for
bifidobacteria, which are the initial gut colonizers in breast-fed
infants. HMO are structurally diverse and composed of several
monosaccharides (glucose, galactose, N-acetylglucosamine,
fucose, or sialic acid). They mainly consist of a lactose core linked
to units (n = 0–15) of lacto-N-biose (type I) or to N-acetyl-
lactosamine (type II; Smilowitz et al., 2014). Bifidobacteria secrete
GH that cleave specific linkages within the HMO molecules
and the best characterized are those synthesized by B. bifidum
which, together with B. longum subsp. infantis, are two abundant
species in breast-fed neonates (Table 1). These species employ
different strategies for HMO utilization. Whereas B. bifidum
has an array of membrane-associated GH, B. longum subsp.
infantis is specialized in the import and intracellular breakdown
of HMO (Garrido et al., 2013; Jae-Han et al., 2013). Moreover
B. longum strains have similar HMO-utilization patterns, whilst
B. bifidum strains are more diverse with some unable to use
fucosylated or sialylated HMO (Garrido et al., 2015). Similarly,
the B. breve HMO utilization profile is strain dependent and,
contrary to B. bifidum, some strains consume fucosylated or
sialilated HMOs. B. breve’s capability to use these HMOs explains
its abundance in breast-fed babies (Ruiz-Moyano et al., 2013).
Some bifidobacteria can also utilize mucins from the mucus
layer coating the intestine. Mucin composition and structure
resemble that of HMO; consisting of a core of different O-glycans,
built on α- and β-linked N-acetyl-galactosamine, galactose, and
N-acetyl-glucosamine residues, which can incorporate fucose
and sialic acid residues (Tailford et al., 2015). B. longum and B.
breve strains’ capability to effectively use mucin carbohydrates,
has been confirmed in vitro (Ruas-Madiedo et al., 2008).
However, GH able to degrade mucins have only been described
in B. bifidum (Table 1). Indeed, in a comparative genomic
study 60% of the GH-encoding genes from B. bifidum were
predicted to breakdown mucin-like glycans and most of them
were exclusively present in this bifidobacterial species (Turroni
et al., 2014). Remarkably, other species could use the mono-
and oligosaccharides released by B. bifidum GH thus evidencing
the existence of cross-feeding mechanisms, as it has been
demonstrated in B. breve and B. bifidum co-cultures (Egan et al.,
2014).
Bifidobacterium capacity to metabolize specific dietary and
host-derived carbohydrates is also dependent on the presence
of specific sugar transport systems. These are crucial for their
competitive establishment in the gut, thus representing one of
the molecular mechanisms by which bifidobacteria interact with
the host. Import sugar mechanisms in bifidobacteria are herein
described (Bottacini et al., 2014).
First, ATP-binding cassette (ABC) systems are active
transporters which couple ATP hydrolysis to translocation
uptake across the cell membrane. They are the most frequent
sugar transporters in bifidobacteria and have been described for
mono- and oligosaccharides in different species (Nishimoto and
Kitaoka, 2007; Wada et al., 2008; Wei et al., 2012), although only
a few of them have been functionally characterized at protein
level (Suzuki et al., 2008; Ejby et al., 2013).
Secondly, some secondary transporters, predicted to consist
of single integral membrane-associated proteins, have been
characterized at protein level in bifidobacteria. These include
permease systems for the uptake of lactose, glucose, and sucrose
(Parche et al., 2006). Secondary transporters encoding genes have
been identified in different bifidobacterial species, although most
of them have not been characterized at protein level (Turroni
et al., 2012).
Proton symporters of the glycoside-pentoside-hexuronide
(GPH) cation symporter family for melibiose and pentosides
were also described in Bifidobacterium (Lee and O’Sullivan, 2010;
Turroni et al., 2012), although they remain to be characterized.
Finally, phosphoenolpyruvate-phosphotransferase (PEP-PTS)
systems were first characterized in the 90’s in B. breve and B.
bifidum at protein level (Lee andO’Sullivan, 2010). Later, genome
sequence availability revealed their wide spread distribution in
bifidobacteria. In particular, B. breve UCC2003 genome contains
four PEP-PTS systems, one of which has been characterized as
a fructose-specific transporter (Mazé et al., 2007). Also, in silico
analysis revealed a putative glucose-specific PEP-PTS uptake
system in B. longum (Lorca et al., 2007). However, genome
analysis of different B. longum strains showed that glucose-
specific PTS transporters are minor in comparison with ABC
transporters (Pokusaeva et al., 2011), thus glucose may be
transported preferentially by secondary permeases (Parche et al.,
2006).
Comparative genomic analysis revealed that sugar PEP-PTS
systems are present in all bifidobacterial genomes, except for
B. animalis subsp. lactis (Lee and O’Sullivan, 2010) which is
hypothesized to have lost most of their carbohydrate transporters
due to extended cultivation under industrial conditions.. In fact,
the capability to utilize variable carbon sources is considered an
adaptation to the gut environment. For instance, the dominant
Bifidobacterium species in infant fecal samples (B. longum and
B. bifidum) is consistent with their inherent ability to use host-
derived oligosaccharides such as mucin and HMO (Bottacini
et al., 2014), and their possession of a wide range of host-derived
carbohydrate transporters, such as those involved in N-biose
import (Suzuki et al., 2008).
REGULATION T-EFFECTOR CELLS
AND Treg
In the absence of disease, the ensemble of molecular
interactions taking place in the human gut results in
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α-glycans: palatinose (1→6); turanose
(1→3); maltotriose and maltose (1→4)
linkages, etc.
α-1,6-glucosidase (GH13) B. breve UCC2003 Pokusaeva et al., 2009;
Kelly et al., 2016




B. adolescentis 22L Duranti et al., 2014
Starch hydrolysates (maltodextrins,
malto-OS, isomalto-OS, maltose, etc.)
α-glucosidases,
α-amylases, etc.
B. longum subsp. longum BBMN68 Liu et al., 2015
Plant ginsenoside and cellobiose β-glucosidase (GH1, GH3) B. animalis subsp. lactis AD011 Kim et al., 2012
Isoflavone glycosides (daidzin) β-glucosidases (GH3) B. pseudocatenulatum IPLA36007 Alegría et al., 2014
β-glucosides (mycotoxins from
cereal-based foods)
β-glucosidases B. adolescentis DSM20083 Michlmayr et al., 2015
β-galactans, β-galacto-OS: (1→4) linkages Endogalactanase (GH53) B. longum NCC2705 Hinz et al., 2005




exo-β-1,3-galactanase B. longum JCM1217 Fujita et al., 2014
Arabinoxylan [β-(1,4)-linked xylosyl
backbone with arabinosyl side chains]
Arabinofuranohydrolase B. adolescentis DSM20083 van den Broek et al., 2005
β-L-arabinofuranosides β-L-arabinobiosidase
(GH121)
B. longum JCM 1217 Fujita et al., 2011
α-1,5-linked arabino-OS α-L-arabinofuranosidase
(GH1)
B. adolescentis ATCC 15703 Suzuki et al., 2013
Plant ginsenoside β-D-xylosidase B. breve K-110 Hyun et al., 2012
Xylo-OS β-D-xylosidase (GH43) B. animalis subsp. lactis BB-12 Viborg et al., 2013




B. longum KN29.1 Bujacz et al., 2011
Flavonoid rhamnoglycosides: (1→6)
linkage
α-L-rhamnosidase B. dentium Bang et al., 2015
β-Mannans (plants) Mannanase (GH5_8) B. animalis subsp. lactis Bl-04 Morrill et al., 2015
HUMAN CARBOHYDRATES: MUCIN AND HMO
α-L-Fucosyl termini residues from
glycoconjugates
1,2-α-L-fucosidase (GH95) B. bifidum JCM1254 Katayama et al., 2004
Mucin-OS (Core 1 type O-glycans) Endo-α-N-
acetylgalactosaminidase
(GH101)
B. longum JCM 1217 Fujita et al., 2005
Mucin 2 (Core 3 type O-glycans) α-N-
acetylgalactosaminidase
(GH129)





B. bifidum JCM 1254 Shimada et al., 2015
HMO and lacto-N-tetraose (type I chain) Lacto-N-biosidase (GH20) B. bifidum JCM1254 Wada et al., 2008
HMO α1,3/4-fucosylated OS 1,3–1,4-α-L-fucosidase B. bifidum JCM1254 Ashida et al., 2009;
Ito et al., 2013




B. bifidum JCM1254 Miwa et al., 2010
HMO sialylOS Exo-α-sialidase (GH33) B. bifidum JCM1254 Kiyohara et al., 2011
Fucosylated HMO α- L-fucosidases (GH29,
GH95)
B. longum subsp. infantis ATCC15697 Sela et al., 2011
HMO (type I chain) + (type II chain) β-1,3-galactosidase +
β-galactosidase
B. longum subsp. infantis ATCC15697 Yoshida et al., 2012
(Continued)
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TABLE 1 | Continued
Substratea Transporter Family Bifidobacteria species References
SUGAR TRANSPORTERS
Arabinoxylo-OS ABC transporter Bifidobacterium animalis subsp. lactis Bl-04 Ejby et al., 2013
Xylo-OSs ABC transporter B. animalis subsp. lactis BB-12 Gilad et al., 2010
Galacto-OS ABC transporter B. breve O’Connell Motherway
et al., 2011a
β-glucans ABC transporter B. longum subsp. infantis Zhao and Cheung, 2013
Galacto-OS, HMO, fructo-OS ABC transporter B. longum subsp. infantis ATCC15697 Kim et al., 2012
HMOs, inulin, Galacto-OS ABC transporter B. longum subsp. infantis ATCC15697 Garrido et al., 2011
galacto-N-biose/lacto-N-biose ABC transporter B. longum JCM1217 Wada et al., 2007
4′-galactosyllactose ABC transporter B. breve Yakult Shigehisa et al., 2015
Cellobiose, galacto-OS, isomaltose,
maltotriose, melibiose, panose, raffinose,
stachyose, xylobiose β-xylo-OS
ABC transporter(s) B. lactis Bl-04 Andersen et al., 2013
lacto-N-biose, galacto-N-biose ABC-transporter B. longum JCM1217 Suzuki et al., 2008
Fructose ABC-transporter B. longum NCC2705 Liu et al., 2011; Wei et al.,
2012
Ribose ABC transporter B. breve UCC2003 Pokusaeva et al., 2010
Glucose Secondary transporter B. animalis DSMZ10140 Briczinski et al., 2008
Fructose PTS B. breve UCC2003 Mazé et al., 2007
Glucose PTS B. longum NCC2705 Parche et al., 2007
Glucose PTS B. longum NCC2705 Parche et al., 2006
Glucose PTS B. animalis subsp. lactis Briczinski et al., 2008
aOS, oligosaccharide(s).
Human carbohydrates: mucin and HMO.
PTS, phosphotransferase system.
the intestinal homeostasis. Specialized epithelial cells
denominated M-cells and antigen presenting cells (APCs)
from the gut-associated lymphoid tissue (GALT) continuously
sample the intestinal content. Interaction of APCs with
the rest of GALT effectors, mainly T and B cells, leads to
immunotolerance against commensal microbes and dietary
components, whilst the capacity of mounting an acute,
quick, and powerful response against enteropathogens is
developed.
Differentiation of commensal and pathogenic bacteria is
based on the presence of pattern recognition receptors (PRR)
on the APC and epithelial cell surfaces. Among them, Toll-
like receptors, NOD-like receptors, C-type lectin receptors,
and RIG-I-like receptors are in charge of recognizing specific
microbial-associated molecular patterns (MAMPs), such as
flagellin, teichoic acids, or lipopolysaccharide among others.
The type and intensity of the downstream and intracellular
signaling cascades deployed after MAMPs-PRR interaction is
essential for the APCs interaction with T-cells, which will finally
determine the nature of the T-cell response. Roughly, T-cell
responses are divided into effector (Th) and regulatory (Treg),
its balance being key in the intestinal homeostasis maintenance
(Maloy and Powrie, 2011). It is generally accepted that
commensal microbiota, by inducing Treg response, modulates
the Th1/Th2 balance favoring immune tolerance against the
gut microbiota (Ventura et al., 2012). Indeed, the classical
MAMP triggering Treg response is the exopolysaccharide A
of the commensal bacterium Bacteroides fragilis, molecule
also involved in the GALT maturation (Mazmanian et al.,
2008).
Bifidobacteria may drive species-specific T-cell responses, as
it was revealed by a series of experiments in which the cytokine
secretion profiles of monocyte-derived dendritic cells (MoDCs)
and full fractions of peripheral bloodmononuclear cells (PBMCs)
were determined (López et al., 2010). Relative levels of key
cytokines (IL-10, IL-17, TNFα among others) suggested a specific
immunomodulation mechanism for each species, as reported
recently for probiotics (Hill et al., 2014). Challenging immature
MoDCs with different strains, followed by co-culture with
allogeneic naïve CD4+ cells and cytokine determination, further
confirmed this effect (López et al., 2011).
Remarkably, B. bifidum LMG13195 appeared to induce a
Treg response in vitro (Figure 1; López et al., 2011). Dendritic
cells challenged with membrane vesicles from this strain
induced naïve CD4+ cells polarization into Treg, as deduced
from the increases in the expression of foxP3 regulation
factor and the CD25 marker (López et al., 2012). Most
likely, surface-associated proteins play a role in this process.
Several proteins have been identified in the bifidobacterial
membrane, among which moonlighting proteins such as
fructose-6-phosphate phosphoketolase or enolase, might be
behind the immunomodulatory effects of the membrane vesicles
(Sánchez et al., 2004). However, the particular proteins involved
in this T-cell polarization have not been identified.
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FIGURE 1 | (A) Schematic representation of the bifidobacterial proteins identified as key mediators of the cross-talk mechanisms with the intestinal environment.
Adhesin-like factors, proteins with immunomodulatory capabilities and glycosyl hydrolases specific for carbon sources encountered in the gastrointestinal tract are
represented. (B) Graphical illustration of the immunomodulatory mechanisms driven by model Bifidobacterium bifidum strains. Different B. bifidum fractions and
molecules induces Treg response, key in maintaining the balance of effector T-cell responses. Membrane vesicles or the extracellular protein TgaA affects dendritic
cells, which induces Treg differentiation after interaction with naïve T-cells. In this process, increased IL-10 secretion, recognition of CD80, and CD86 by CD28 in naïve
T-cells and release of IL-2 are key for Treg response development.
Other immunogenic extracellular proteins are pili,
proteinaceous structures that self-assemble into filaments
on the bacterial surface (Ventura et al., 2012). Specifically,
one sortase-dependent pili from B. bifidum PRL2010 induced
TNFα production during transient colonization of the murine
mucosa, which acted as a macrophage-activating factor during
Th1 (Turroni et al., 2013). Another surface-protein able
to influence T-cell responses is TgaA from B. bifidum, a
peptidoglycan-derived enzyme able to induce DC activation
and IL-2 production (Guglielmetti et al., 2014). IL-2 is one of
the main cytokines supporting Treg proliferation, which are
characterized by the presence of CD25, the T-cell receptor for
that interleukin (Zelante et al., 2012). Despite the evidence
supporting an immunomodulation role of bifidobacteria,
only a few surface-associated proteins have been identified as
possible mediators of this effect on a limited number of in vitro
experiments. Identifying the molecules behind this effect and
confirming their efficacy in clinical trials, might provide keys
to ameliorate diseases characterized by exacerbated immune
responses.
INDUCTION OF IgA PRODUCTION
Immunoglobulin A (IgA) is the most abundant antibody
in human mucosa and modulates immune responses against
commensal bacteria, preventing direct contact with immune cells
(Peterson et al., 2007; Brandtzaeg, 2013). Globally, 40% of gut
bacteria are IgA-coated although these values are species- and
strain-dependent (Talja et al., 2014). In healthy individuals, IgA
coating of bifidobacteria is higher than that of other commensals
(van der Waaij et al., 2004; De Palma et al., 2010), explaining
the immune tolerance to high densities of bifidobacteria. In fact,
44 proteins from B. longum and 24 from B. adolescentis were
recognized by IgA (Talja et al., 2014). IgA-coated bifidobacteria
also enhanced probiotic attachment to Caco-2 cells and increased
production of mucosal defense molecules (Mathias et al., 2010).
Levels of IgA-coated gut commensals are altered in dysbiosis
states such as those described in coeliac disease (De Palma et al.,
2010), inflammatory bowel disease (van der Waaij et al., 2004),
or autoimmunity disorders (Talja et al., 2014). Coeliac children
showed reduced levels of bifidobacteria and IgA-coated bacteria
(De Palma et al., 2010). Conversely, IgA from children developing
islet autoimmunity, bound to more B. adolescentis antigens
than those from healthy controls (Talja et al., 2014). Morevoer,
bifidobacterial supplements modulate IgA production (Holscher
et al., 2012; Kandasamy et al., 2014). A probiotic mixture
containing bifidobacteria increased IgA and reduced diarrhea
following rotavirus vaccination in a gnotobiotic pig model
(Kandasamy et al., 2014). B. animalis Bb12 supplementation
to formula-fed infants increased IgA in feces and, in those
delivered by C-section, enhanced immune responses as reflected
by higher anti-rotavirus and anti-poliovirus IgA production
following vaccination (Holscher et al., 2012). The bifidogenic
effect of galactooligosaccharides also correlated to increased IgA
production (Vulevic et al., 2013; Paineau et al., 2014). Further,
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research to specifically delineate the bifidobacterial molecules
mediating IgA induction and interaction is necessary.
OTHER BIFIDOBACTERIUM EFFECTORS
OF THE HOST-MICROBE DIALOGUE
A few extracellular proteins, with important physiological roles
not discussed in the previous sections deserve further attention.
Some Bifidobacterium strains produce surface-exposed Serine
Protease Inhibitors of proteinaceous nature (serpins), which
participate in a variety of physiological processes. The serpin
produced by B. longumNCC2705 inhibits elastase-like proteases,
including neutrophil or pancreatic elastases, thus suggesting a
role in protecting bifidobacteria against exogenous proteases
and potential anti-inflammatory activity (Ivanov et al., 2006).
Remarkably, serpins are widely distributed in bifidobacteria and
several species harbor serpin-encoding genes in their genomes
(Turroni et al., 2010).
CONCLUSIONS
Some Bifidobacterium proteins have been identified as mediators
of the cross-talk bifidobacteria-host, providing bases to
understand their beneficial traits and opening new avenues to
conceive bifidobacterial-based therapeutic strategies. However,
in most cases, the molecular mechanisms triggered remain
unknown what has limited their translation into improved
functional supplements. Identifying targets for intervention at
intestinal level and developing appropriate models to search for
bifidobacterial mediators is required to delineate strategies that
fine-tune disease-associated alterations in the microbiota-host
interplay.
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